CRIS (Curis Inc)
Insider Trading Activity
Every open-market purchase and sale reported by CRIS officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-09 | James E Dentzer | President & CEO | A | — | — |
| 2026-07-09 | Diantha Duvall | CFO | A | — | — |
| 2026-07-09 | Anne Elizabeth Borgman | Director | A | — | — |
| 2026-07-09 | KENNETH I KAITIN | Director | A | — | — |
| 2026-07-09 | Jonathan B. Zung | CDO | A | — | — |
| 2026-07-09 | John Hohneker | Director | A | — | — |
| 2026-07-09 | Marc Rubin | Director | A | — | — |
| 2026-07-09 | MARTYN D GREENACRE | Director | A | — | — |
| 2026-04-01 | KENNETH I KAITIN | Director | Buy | — | — |
| 2026-03-23 | James E Dentzer | President & CEO | C | — | — |
| 2026-03-23 | Jonathan B. Zung | CDO | C | — | — |
| 2026-03-23 | Marc Rubin | Director | C | — | — |
| 2026-03-23 | Diantha Duvall | CFO | C | — | — |
| 2026-03-23 | Ahmed MD Hamdy | CMO | C | — | — |
| 2026-03-18 | Ahmed MD Hamdy | CMO | A | — | — |
| 2026-03-18 | Diantha Duvall | CFO | A | — | — |
| 2026-03-18 | Marc Rubin | Director | A | — | — |
| 2026-03-18 | James E Dentzer | President & CEO | A | — | — |
| 2026-03-18 | Jonathan B. Zung | CDO | A | — | — |
| 2025-05-22 | MARTYN D GREENACRE | Director | A | — | — |
| 2025-05-22 | KENNETH I KAITIN | Director | A | — | — |
| 2025-05-22 | James E Dentzer | President & CEO | A | — | — |
| 2025-05-22 | Jonathan B. Zung | CDO | A | — | — |
| 2025-05-22 | Marc Rubin | Director | A | — | — |
| 2025-05-22 | Anne Elizabeth Borgman | Director | A | — | — |
| 2025-05-22 | Diantha Duvall | CFO | A | — | — |
| 2025-05-22 | John Hohneker | Director | A | — | — |
| 2025-05-05 | Ahmed MD Hamdy | CMO | A | — | — |
| 2025-01-30 | Diantha Duvall | CFO | A | — | — |
| 2025-01-30 | John Hohneker | Director | A | — | — |
| 2025-01-30 | James E Dentzer | President & CEO | A | — | — |
| 2025-01-30 | Anne Elizabeth Borgman | Director | A | — | — |
| 2025-01-30 | KENNETH I KAITIN | Director | A | — | — |
| 2025-01-30 | MARTYN D GREENACRE | Director | A | — | — |
| 2025-01-30 | Jonathan B. Zung | CDO | A | — | — |
| 2025-01-30 | Marc Rubin | Director | A | — | — |
| 2024-05-23 | Diantha Duvall | CFO | A | — | — |
| 2024-05-23 | Jonathan B. Zung | CDO | A | — | — |
| 2024-05-23 | James E Dentzer | President & CEO | A | — | — |
| 2024-05-23 | Marc Rubin | Director | A | — | — |
| 2024-05-23 | MARTYN D GREENACRE | Director | A | — | — |
| 2024-05-23 | Anne Elizabeth Borgman | Director | A | — | — |
| 2024-05-23 | KENNETH I KAITIN | Director | A | — | — |
| 2024-05-23 | John Hohneker | Director | A | — | — |
| 2023-05-03 | Jonathan B. Zung | CDO | A | — | — |
| 2023-01-24 | Marc Rubin | Director | A | — | — |
| 2023-01-24 | Robert Martell | Head of Research & Development | A | — | — |
| 2023-01-24 | James E Dentzer | President & CEO | A | — | — |
| 2023-01-24 | MARTYN D GREENACRE | Director | A | — | — |
| 2023-01-24 | Diantha Duvall | CFO | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 13,664 | — |
| — | President & CEO | 7,436 | — |
| — | — | 4,097 | — |
| — | CFO | 3,885 | — |
| — | CDO | 3,333 | — |
| — | CMO | 3,333 | — |
| — | 10%+ Owner | 3,125 | — |
| — | Director | 1,405 | — |
| — | Director | 570 | — |
| — | Director | 488 | — |
| — | President & CEO | 161 | — |
| — | Director | 106 | — |
| — | Chief Medical Officer | 85 | — |
| — | Director | 72 | — |
| — | Director | 65 | — |
| — | Head of Research & Development | 58 | — |
| — | Director | 56 | — |
| — | CFO | 54 | — |
| — | VP, Tech Management | 40 | — |
| — | Director | 22 | — |
| — | Director | 15 | — |
| — | Director | 10 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CRIS quote page; the site-wide leaderboard is on the insider transactions hub.